ABCSG-Publications (peer reviewed) 2001-2005
The publication of study results is an essential mandate of the ABCSG. Therapy improvements can only be made accessible to the entire medical-scientific community through publications. As a result, our knowledge of cancer is continuously increasing and the chances of winning the battle against it increase.
The publications listed here are the result of many years of successful work by the ABCSG.
Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group
Filipits M, Pohl G, Rudas M, Dietze O, Lax S, Grill R, Pirker R, Zielinski C, Hausmaninger H, Kubista E, Samonigg H, Jakesz R
Journal of Clinical Oncology
https://www.ncbi.nlm.nih.gov/pubmed/15718312
Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial
Jakesz R, Jonat W, Gnant M, Mittlböck M, Greil R, Tausch Ch, Hilfrich J, Kwasny W, Menzel Ch, Samonigg H, Seifer M, Gademann G, Kaufmann M
The Lancet
https://www.ncbi.nlm.nih.gov/pubmed/16084253
Trastuzumab after Adjuvant Chemotherapy in HER2-positive Breast Cancer
Piccart-Gebhart M, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios C, Steger G, Huang C, Andersson M, Inbar M, Lichinitser M, Láng I, Nitz U, Iwata H, Thomssen C, Lorisch C, Suter T, Rüschoff J, Süt´ö, Greatorex V, Ward C, Straehle C, McFadden E, Dolci S, Gelber S
The New England Journal of Medicine
https://www.ncbi.nlm.nih.gov/pubmed/16236737
A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for Stage III colon cancer
Schippinger W, Jagoditsch M, Sorré C, Gnant M, Steger G, Hausmaninger H, Mlineritsch B, Schaberl-Moser R, Mischinger HJ, Hofbauer F, Holzberger P, Mittlböck M, Jakesz R
British Journal of Cancer
Empfehlungen zu Diagnostik und multimodaler Primärtherapie des Rektumkarzinoms 2004
ABCSG, ACO/ASSO, ÖGC, ÖGHO, ÖGP, ÖGRO, ÖRG
Wiener Klinische Wochenschrift 2004.: 10.1007/s00508-005-0323-1
Amenorrhoea, aromatase inhibitors, tamoxifen or a combination in premenopausal women.
Jakesz R
European Journal of Cancer
https://cyberleninka.org/article/n/275469
Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer.
Schoppmann SF, Bayer G, Aumayr K, Taucher S, Geleff S, Rudas M, Kubista E, Hausmaninger H, Samonigg H, Gnant M, Jakesz R, Horvat R
Annals of Surgery
https://www.ncbi.nlm.nih.gov/pubmed/15273556
The impact of progesterone receptor in prediction of complete pathological response to preoperative chemotherapy in primary breast cancer patients.
Taucher S, Rudas M, Gnant M, Dubsky P, Sporn E, Roka S, Bachleitner T, Fitzal F, Kandioler D, Wenzel C, Steger G, Draxler W, Mittlböck M, Jakesz R
European Surgery
Incidence of liver metastases in patients receiving adjuvant chemotherapy after lymph node positive primary colon cancer
Gruenberger T, Schwanzer E, Samonigg H, Hausmaninger H, Jakesz R
Journal of Gastrointestinal Surgery
Pelvic radiological imaging: a surgeon’s perspective
Herbst F
European Journal of Radiology
https://www.ncbi.nlm.nih.gov/pubmed/12880994
Significant increase in breast conservation in 16 years of trials conducted by the Austrian Breast & Colorectal Cancer Study Group (ABCSG)
Jakesz R, Samonigg H, Gnant M, Kubista E, Depisch D, Kolb R, Mlineritsch B, Mischinger HJ, Menzel RC, Steindorfer P, Kwasny W, Tausch C, Stierer M, Taucher S, Seifert M, Hausmaninger H
Annals of Surgery
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1514470/
In reply to: Paradigm shift in adjuvant treatment of receptor positive premenopausal breast cancer patients? Not yet.
Jakesz R
Journal of Clinical Oncology
Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor negative breast cancer patients
Ploner F, Jakesz R, Hausmaninger H, Kolb R, Stierer M, Fridrik M, Steindorfer P, Gnant M, Haider K, Mlineritsch B, Tschurtschenthaler G, Steger G, Seifert M, Kubista E, Samonigg H
Onkologie
https://www.ncbi.nlm.nih.gov/pubmed/12771518
High p27 Kip1 expression predicts superior relapse-free and overall survival for premenopausal women with early-stage breast cancer receiving adjuvant treatment with tamoxifen plus goserelin
Pohl G, Rudas M, Dietze O, Lax S, Markis E, Pirker R, Zielinski C, Hausmaninger H, Kubista E, Samonigg H, Jakesz R, Filiptis M
Journal of Clinical Oncology
https://www.ncbi.nlm.nih.gov/pubmed/14512390
Randomized trial of tamoxifen vs tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian Breast and Colorectal Cancer Study Group Trial 6.
Schmid M, Jakesz R, Samonigg H, Kubista E, Gnant M, Menzel C, Seifert M, Haider K, Taucher S, Mlineritsch B, Steindorfer P, Kwasny W, Stierer M, Tausch C, Fridrik M, Wette V, Steger G, Hausmaninger H
Journal of Clinical Oncology
https://www.ncbi.nlm.nih.gov/pubmed/12637461
Dendritic Cell-Based Vaccination in Solid Cancer
Stift A, Dubsky P, Bachleitner-Hofmann T, Schueller G, Zontsich T, Benkoe T, Radelbauer K, Brostjan C, Jakesz R, Gnant M
Journal of Clinical Oncology
https://www.ncbi.nlm.nih.gov/pubmed/12506182
Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy
Taucher S, Rudas M, Gnant M, Thomanek K, Dubsky P, Roka S, Bachleitner T, Kandioler D, Wenzel C, Steger G, Mittlböck M, Jakesz R
Endocrine-Related Cancer
https://www.ncbi.nlm.nih.gov/pubmed/12653672
Preventive mastectomy in patients at breast cancer risk due to genetic alterations in the BRCA1 and BRCA2 gene
Taucher S, Gnant M, Jakesz R
Langenbecks Archive of Surgery
https://www.ncbi.nlm.nih.gov/pubmed/12690474
Overexpression of Id-1 is associated with poor clinical outcome in node negative breast cancer
Schoppmann SF, Schindl M, Bayer G, Aumayr K, Dienes J, Horvat R, Rudas M, Gnant M, Jakesz R, Birner P
Wiley-Liss DOI 10.1002/ijc.11009
https://www.ncbi.nlm.nih.gov/pubmed/12640673
Impact of pretreatment thromboyctosis on survival in primary breast cancer
Taucher S, Salat A, Gnant M, Kwasny W, Mlineritsch B, Menzel RC, Schmid M, Smola MG, Stierer M, Tausch C, Galid A, Steger G, Jakesz R
Thrombosis & Haemostasis
Identification of Sentinel Lymph Nodes in Breast Cancer by Lymphoscintingraphy and Gamma Probe Guidance: Dependence on Route of Injection and Tumour Location
Gallowitsch JH, Konstantiniuk P, Jörg L, Urbania A, Kugler F, Peschina W, Hatzl-Griesenhofer M, Zettinig G
European Surgery
https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1563-2563.2002.02072.x
The importance of sentinel node biopsy in breast surgery
Haid A, Schrenk P, Roka S, Tausch C, Pichler-Gebhard B, Rudas M, Zimmermann G
European Surgery
https://onlinelibrary.wiley.com/doi/abs/10.1046/j.1563-2563.2002.02065.x
Chemotherapy versus hormonal adjuvant treatment in premenopausal patients with breast cancer
Jakesz R, Hausmaninger H, Samonigg H
European Journal of Cancer
https://www.ncbi.nlm.nih.gov/pubmed/11818196
Randomized adjuvant trial of tamoxifen and goserelin versus cyclophospamide, methotrexate, and fluorouracil: Evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer
Jakesz R, Hausmaninger H, Kubista E, Gnant M, Menzel C, Bauernhofer T, Seifert M, Haider K, Mlineritsch B, Steindorfer P, Kwasny W, Fridrik M, Steger G, Wette V, Samonigg H
Journal of Clinical Oncology
https://www.ncbi.nlm.nih.gov/pubmed/12488405
Standards in der Mamma-Ca-Therapie
Jakesz R
Wiener Klinische Wochenschrift
Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer
Schindl M, Schoppmann F, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E, Birner P, Oberhuber G
Clinical Cancer Research
https://www.researchgate.net/publication/11313017.. Breast_Cancer
Survival of women with breast cancer in Austria by age, stage and period of diagnosis
Vutuc Chr, Waldhoer T, Klimot J, Haidinger G, Jakesz R, Kubist E, Zielinski C
Wiener Klinische Wochenschrift
Evaluation of the United States Food and Drug Administration approved Scoring and Test System of HER-2 Protein Expression in Breast Cancer
Birner P, Oberhuber G, Stani J, Reithofer C, Samonigg H, Hausmaninger H, Kubista E, Kwasny W, Kandioler-Eckersberger D, Gnant M, Jakesz R
Clinical Cancer Research
https://www.ncbi.nlm.nih.gov/pubmed/11410505
Prognostic relevance of three histological grading methods in breast cancer
Latinovic L, Heinze G, Birner P, Samonigg H, Hausmaninger H, Kubista E, Kwasny W, Gnant M, Jakesz R, Oberhuber G
International Journal of Oncology
Share on